Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dyne Therapeutics Inc
(NQ:
DYN
)
30.78
+0.05 (+0.16%)
Streaming Delayed Price
Updated: 3:05 PM EDT, Oct 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dyne Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
June 04, 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
Via
InvestorPlace
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
May 30, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
May 28, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Recap: Dyne Therapeutics Q4 Earnings
March 05, 2024
Via
Benzinga
Modine Manufacturing Posts Mixed Q4 Results, Joins Viasat, Lululemon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
May 22, 2024
Via
Benzinga
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
May 21, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
May 20, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Why Is Dyne Therapeutics Stock Soaring On Monday?
May 20, 2024
Dyne Therapeutics reported promising Phase 1/2 trial data for DYNE-101 in myotonic dystrophy type 1 and DYNE-251 in Duchenne muscular dystrophy. Improvements in splicing correction, myotonia, muscle...
Via
Benzinga
Tech Surge Boosts Nasdaq To Record Highs
May 20, 2024
The Nasdaq Composite Index is up triple digits and marking new record highs, thanks to rising tech stocks.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
May 20, 2024
Dyne Therapeutics is looking to take on Sarepta Therapeutics in DMD.
Via
Investor's Business Daily
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
May 20, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
May 20, 2024
Pre-market stock movers are a great way to start the trading week and we have all of the hottest news worth reading about on Monday!
Via
InvestorPlace
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
May 20, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
May 19, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024
May 02, 2024
DYN stock results show that Dyne Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 02, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
March 27, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
March 27, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 25, 2024
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
Via
Benzinga
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
March 25, 2024
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Dyne Therapeutics Announces CEO Transition
March 25, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
March 14, 2024
Cantor Fitzgerald initiates coverage on Avidity Biosciences highlighting a robust pipeline led by del-desiran, a promising treatment for Myotonic dystrophy type 1. With strong management, proven...
Via
Benzinga
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
March 13, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Chardan Capital Maintains Buy Rating for Dyne Therapeutics: Here's What You Need To Know
March 08, 2024
Via
Benzinga
Piper Sandler Maintains Overweight Rating for Dyne Therapeutics: Here's What You Need To Know
March 06, 2024
Via
Benzinga
DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q4 2023
March 05, 2024
DYN stock results show that Dyne Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 05, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
March 01, 2024
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Top 4 Health Care Stocks You May Want To Dump In February
February 15, 2024
As of Feb. 15, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
February 14, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.